Chengdu Easton Valuation Multiples

Chengdu Easton is valued at $1.2B as of October 2026, a 4.8x revenue multiple. In the last 12 months, Chengdu Easton revenue was $208M and Chengdu Easton EBITDA was $61M.

Chengdu Easton Overview

About Chengdu Easton

Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.


Founded

2009

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $208M
EBITDA: $61M

EV

$994M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Chengdu Easton Financials

Chengdu Easton reported last 12-month revenue of $208M and EBITDA of $61M.

In the same LTM period, Chengdu Easton generated $156M in gross profit, $61M in EBITDA, and $42M in net income.

Revenue (LTM)


Chengdu Easton P&L

In the most recent fiscal year, Chengdu Easton reported revenue of $199M and EBITDA of $57M.

Chengdu Easton is profitable as of last fiscal year, with gross margin of 75%, EBITDA margin of 29%, and net margin of 21%.

See analyst estimates for Chengdu Easton
LTMLast FY202320242025202620272028
Revenue$208M$199M$166M$200M$199M
Gross Profit$156M$150M$133M$150M$150M
Gross Margin75%75%80%75%75%
EBITDA$61M$57M$47M$50M$57M
EBITDA Margin29%29%28%25%29%
EBIT Margin22%19%19%16%19%
Net Profit$42M$43M$34M$35M$43M
Net Margin20%21%20%18%21%
Net Debt-($106M)---

Financial data powered by Morningstar, Inc.

Chengdu Easton Stock Performance

Chengdu Easton has current market cap of $1.2B, and enterprise value of $994M.

Market Cap Evolution


Chengdu Easton's stock price is $6.85.

Chengdu Easton share price decreased by 10.3% in the last 30 days, and by 18.1% in the last year.

Chengdu Easton has an EPS (earnings per share) of $0.24.

See more trading valuation data for Chengdu Easton
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$994M$1.2B0.8%-10.3%3.2%-18.1%$0.24

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Chengdu Easton Valuation Multiples

Chengdu Easton trades at 4.8x EV/Revenue multiple, and 16.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Chengdu Easton

EV / Revenue (LTM)


Chengdu Easton Financial Valuation Multiples

As of October 20, 2026, Chengdu Easton has market cap of $1.2B and EV of $994M.

Chengdu Easton has a P/E ratio of 28.6x.

LTMLast FY202320242025202620272028
EV/Revenue4.8x5.0x6.0x5.0x5.0x
EV/EBITDA16.4x17.4x21.1x19.8x17.4x
EV/EBIT21.3x26.3x32.3x30.2x26.3x
EV/Gross Profit6.4x6.6x7.5x6.6x6.6x
P/E28.6x28.4x36.0x34.2x28.4x
EV/FCF-37.2x67.0x46.0x37.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Chengdu Easton Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Chengdu Easton Margins & Growth Rates

Chengdu Easton grew revenue by 6% and EBITDA by 9% in the last fiscal year.

In the most recent fiscal year, Chengdu Easton reported gross margin of 75%, EBITDA margin of 29%, and net margin of 21%.

See estimated margins and future growth rates for Chengdu Easton

Chengdu Easton Margins

Last FY202420252026202720282029
Gross Margin75%75%75%75%
EBITDA Margin29%25%29%29%
EBIT Margin19%16%19%22%
Net Margin21%18%21%20%
FCF Margin13%11%13%-

Chengdu Easton Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%21%(0%)6%
Gross Profit Growth6%13%0%6%
EBITDA Growth9%7%14%9%
EBIT Growth24%7%15%24%
Net Profit Growth(0%)5%20%(0%)
FCF Growth-46%24%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Chengdu Easton Operational KPIs

Chengdu Easton's Rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Chengdu Easton's Rule of X is 45% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Chengdu Easton
LTMLast FY202320242025202620272028
Rule of 4042%36%---
Bessemer Rule of X62%45%---
S&M Expenses to Revenue30%26%29%28%26%
G&A Expenses to Revenue13%2%2%2%2%
R&D Expenses to Revenue21%20%21%20%20%
Opex to Revenue-56%61%59%56%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Chengdu Easton Competitors

Chengdu Easton competitors include Kardigan, Sawai Group Holdings, OPKO Health, Damora Therapeutics, GNI Group, Omeros, BeBetter Med, PYC Therapeutics, Syndax and Silence Therapeutics.

Most Chengdu Easton public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Kardigan-($197M)--(3.2x)-
Sawai Group Holdings$1.3B$202M1.4x1.4x8.9x7.3x
OPKO Health$607M($56M)2.1x2.3x(23.2x)(11.3x)
Damora Therapeutics-($211M)--(3.7x)(5.0x)
GNI Group$170M($15M)7.3x4.9x(83.8x)304.8x
Omeros-($7M)-11.6x(173.8x)-
BeBetter Med-($21M)--(44.7x)-
PYC Therapeutics$14M($40M)65.3x94.2x(23.5x)(16.1x)

This data is available for Pro users. Sign up to see all Chengdu Easton competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Chengdu Easton

When was Chengdu Easton founded?Chengdu Easton was founded in 2009.
Where is Chengdu Easton headquartered?Chengdu Easton is headquartered in China.
Is Chengdu Easton publicly listed?Yes, Chengdu Easton is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Chengdu Easton?Chengdu Easton trades under 688513 ticker.
When did Chengdu Easton go public?Chengdu Easton went public in 2020.
Who are competitors of Chengdu Easton?Chengdu Easton main competitors include Kardigan, Sawai Group Holdings, OPKO Health, Damora Therapeutics, GNI Group, Omeros, BeBetter Med, PYC Therapeutics, Syndax, Silence Therapeutics.
What is the current market cap of Chengdu Easton?Chengdu Easton's current market cap is $1.2B.
What is the current revenue of Chengdu Easton?Chengdu Easton's last 12 months revenue is $208M.
What is the current revenue growth of Chengdu Easton?Chengdu Easton revenue growth (NTM/LTM) is 13%.
What is the current EV/Revenue multiple of Chengdu Easton?Current revenue multiple of Chengdu Easton is 4.8x.
What is the current EBITDA of Chengdu Easton?Chengdu Easton's last 12 months EBITDA is $61M.
What is Chengdu Easton's EBITDA margin?Chengdu Easton's last 12 months EBITDA margin is 29%.
What is the current EV/EBITDA multiple of Chengdu Easton?Current EBITDA multiple of Chengdu Easton is 16.4x.
How many companies Chengdu Easton has acquired to date?Chengdu Easton hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Chengdu Easton has invested to date?Chengdu Easton hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Chengdu Easton

Lists including Chengdu Easton

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial